184 related articles for article (PubMed ID: 38539479)
1. Biomarkers of Immunotherapy Response in Patients with Non-Small-Cell Lung Cancer: Microbiota Composition, Short-Chain Fatty Acids, and Intestinal Permeability.
Moratiel-Pellitero A; Zapata-García M; Gascón-Ruiz M; Sesma A; Quílez E; Ramirez-Labrada A; Martínez-Lostao L; Domingo MP; Esteban P; Yubero A; Barbero-Herranz R; Moreno-Blanco A; Paño JR; Lastra R; Pardo J; Isla D; Del Campo R; Gálvez E
Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539479
[TBL] [Abstract][Full Text] [Related]
2. Cancer immunotherapy resistance: The impact of microbiome-derived short-chain fatty acids and other emerging metabolites.
Hersi F; Elgendy SM; Al Shamma SA; Altell RT; Sadiek O; Omar HA
Life Sci; 2022 Jul; 300():120573. PubMed ID: 35469916
[TBL] [Abstract][Full Text] [Related]
3. Commensal microbiota contributes to predicting the response to immune checkpoint inhibitors in non-small-cell lung cancer patients.
Zhang C; Wang J; Sun Z; Cao Y; Mu Z; Ji X
Cancer Sci; 2021 Aug; 112(8):3005-3017. PubMed ID: 34028936
[TBL] [Abstract][Full Text] [Related]
4. Gut Microbiota Richness and Composition and Dietary Intake of Overweight Pregnant Women Are Related to Serum Zonulin Concentration, a Marker for Intestinal Permeability.
Mokkala K; Röytiö H; Munukka E; Pietilä S; Ekblad U; Rönnemaa T; Eerola E; Laiho A; Laitinen K
J Nutr; 2016 Sep; 146(9):1694-700. PubMed ID: 27466607
[TBL] [Abstract][Full Text] [Related]
5. Microbiota and Lung Cancer. Opportunities and Challenges for Improving Immunotherapy Efficacy.
Ocáriz-Díez M; Cruellas M; Gascón M; Lastra R; Martínez-Lostao L; Ramírez-Labrada A; Paño JR; Sesma A; Torres I; Yubero A; Pardo J; Isla D; Gálvez EM
Front Oncol; 2020; 10():568939. PubMed ID: 33117698
[TBL] [Abstract][Full Text] [Related]
6. Short-chain fatty acids: microbial metabolites that alleviate stress-induced brain-gut axis alterations.
van de Wouw M; Boehme M; Lyte JM; Wiley N; Strain C; O'Sullivan O; Clarke G; Stanton C; Dinan TG; Cryan JF
J Physiol; 2018 Oct; 596(20):4923-4944. PubMed ID: 30066368
[TBL] [Abstract][Full Text] [Related]
7. Inflammatory bowel disease is associated with increased gut-to-blood penetration of short-chain fatty acids: A new, non-invasive marker of a functional intestinal lesion.
Jaworska K; Konop M; Bielinska K; Hutsch T; Dziekiewicz M; Banaszkiewicz A; Ufnal M
Exp Physiol; 2019 Aug; 104(8):1226-1236. PubMed ID: 31243807
[TBL] [Abstract][Full Text] [Related]
8. The Tumor and Host Immune Signature, and the Gut Microbiota as Predictive Biomarkers for Immune Checkpoint Inhibitor Response in Melanoma Patients.
Tomela K; Pietrzak B; Schmidt M; Mackiewicz A
Life (Basel); 2020 Sep; 10(10):. PubMed ID: 32992737
[TBL] [Abstract][Full Text] [Related]
9. Short-chain fatty acids affect the development of inflammatory bowel disease through intestinal barrier, immunology, and microbiota: A promising therapy?
Peng K; Xia S; Xiao S; Yu Q
J Gastroenterol Hepatol; 2022 Sep; 37(9):1710-1718. PubMed ID: 35906780
[TBL] [Abstract][Full Text] [Related]
10. Gut microbiota diversity and specific composition during immunotherapy in responders with non-small cell lung cancer.
Shoji F; Yamaguchi M; Okamoto M; Takamori S; Yamazaki K; Okamoto T; Maehara Y
Front Mol Biosci; 2022; 9():1040424. PubMed ID: 36353732
[TBL] [Abstract][Full Text] [Related]
11. Gut Microbiota Are a Novel Source of Biomarkers for Immunotherapy in Non-Small-Cell Lung Cancer (NSCLC).
Del Giudice T; Staropoli N; Tassone P; Tagliaferri P; Barbieri V
Cancers (Basel); 2024 May; 16(10):. PubMed ID: 38791885
[TBL] [Abstract][Full Text] [Related]
12. The gut microbiota is associated with the small intestinal paracellular permeability and the development of the immune system in healthy children during the first two years of life.
Kaczmarczyk M; Löber U; Adamek K; Węgrzyn D; Skonieczna-Żydecka K; Malinowski D; Łoniewski I; Markó L; Ulas T; Forslund SK; Łoniewska B
J Transl Med; 2021 Apr; 19(1):177. PubMed ID: 33910577
[TBL] [Abstract][Full Text] [Related]
13. Exploiting the Zonulin Mouse Model to Establish the Role of Primary Impaired Gut Barrier Function on Microbiota Composition and Immune Profiles.
Miranda-Ribera A; Ennamorati M; Serena G; Cetinbas M; Lan J; Sadreyev RI; Jain N; Fasano A; Fiorentino M
Front Immunol; 2019; 10():2233. PubMed ID: 31608059
[TBL] [Abstract][Full Text] [Related]
14. Dynamic gut microbiota changes in patients with advanced malignancies experiencing secondary resistance to immune checkpoint inhibitors and immune-related adverse events.
Zeng Y; Shi Q; Liu X; Tang H; Lu B; Zhou Q; Xu Y; Chen M; Zhao J; Li Y; Qian J; Wang M; Tan B
Front Oncol; 2023; 13():1144534. PubMed ID: 37114123
[TBL] [Abstract][Full Text] [Related]
15. Alterations in Circulating Fatty Acid Are Associated With Gut Microbiota Dysbiosis and Inflammation in Multiple Sclerosis.
Saresella M; Marventano I; Barone M; La Rosa F; Piancone F; Mendozzi L; d'Arma A; Rossi V; Pugnetti L; Roda G; Casagni E; Cas MD; Paroni R; Brigidi P; Turroni S; Clerici M
Front Immunol; 2020; 11():1390. PubMed ID: 32733460
[No Abstract] [Full Text] [Related]
16. [Association between Immunotherapy with Immune Checkpoint Inhibitors(Anti-PD-1 Antibodies)and Intestinal Microbiota].
Ozaki Y; Suzuki Y; Nishiyama K; Suzutani T; Suzuki H
Gan To Kagaku Ryoho; 2021 Sep; 48(9):1096-1099. PubMed ID: 34521783
[TBL] [Abstract][Full Text] [Related]
17. Identification of a predictive metabolic signature of response to immune checkpoint inhibitors in non-small cell lung cancer: METABO-ICI clinical study protocol.
Sannicolo S; Giaj Levra M; Le Gouellec A; Aspord C; Boccard J; Chaperot L; Toussaint B; Moro-Sibilot D; Hannani D; Toffart AC
Respir Med Res; 2021 Nov; 80():100845. PubMed ID: 34242975
[TBL] [Abstract][Full Text] [Related]
18. Exploring the relationship between intestinal microbiota and immune checkpoint inhibitors in the treatment of non-small cell lung cancer: insights from the "lung and large intestine stand in exterior-interior relationship" theory.
Li L; Zhong H; Wang Y; Pan Z; Xu S; Li S; Zeng G; Zhang W; Li J; He L
Front Cell Infect Microbiol; 2024; 14():1341032. PubMed ID: 38415012
[TBL] [Abstract][Full Text] [Related]
19. Gut microbiota and its metabolites in non-small cell lung cancer and brain metastasis: from alteration to potential microbial markers and drug targets.
Jiang H; Zeng W; Zhang X; Li Y; Wang Y; Peng A; Cao D
Front Cell Infect Microbiol; 2023; 13():1211855. PubMed ID: 38304459
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of Qingyi Decoction in Severe Acute Pancreatitis-Associated Acute Lung Injury via Gut Microbiota: Targeting the Short-Chain Fatty Acids-Mediated AMPK/NF-κB/NLRP3 Pathway.
Wang Z; Liu J; Li F; Ma S; Zhao L; Ge P; Wen H; Zhang Y; Liu X; Luo Y; Yao J; Zhang G; Chen H
Microbiol Spectr; 2023 Aug; 11(4):e0366422. PubMed ID: 37338348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
